Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.47 |
| ▸ | BACE1 | P56817 | 10/20 | 0.42 |
| ▸ | CTSD | P07339 | 2/20 | 0.42 |
| ▸ | BMP1 | P13497 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GNPAT | O15228 | 1/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28081126 | 0.85 | DPP4 (0.58) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL7405823 | 0.85 | DPP4 (0.43) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL2223562 | 0.83 | MME (0.40) | BACE1CTSDGNPATBACE2 | |
| SCHEMBL2196474 | 0.82 | DPP4 (0.47) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL2184922 | 0.82 | DPP4 (0.47) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL29478400 | 0.82 | BACE1 (0.54) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL31514361 | 0.81 | ALOX15 (0.50) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL2182137 | 0.80 | OPRD1 (0.38) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL30656940 | 0.80 | BMP1 (0.58) | DPP4DPP8DPP9BACE1CTSD | |
| SCHEMBL2182252 | 0.79 | DPP4 (0.38) | DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | DPP4 193/4885DPP8 274/4885DPP9 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.